Bafna Pharmaceuticals Limited (IN:BAFNAPH)
:BAFNAPH
BAFNAPH Stock Chart & Stats
₹154.65
-₹1.34(-1.60%)
At close: 4:00 PM EST
₹154.65
-₹1.34(-1.60%)
Day’s Range― - ―
52-Week Range₹71.65 - ₹204.95
Previous CloseN/A
Volume2.58K
Average Volume (3M)1.19K
Market Cap
₹2.63B
Enterprise Value₹3.02B
Total Cash (Recent Filing)₹19.67M
Total Debt (Recent Filing)₹324.03M
Price to Earnings (P/E)48.5
Beta0.30
Next Earnings
Jun 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.78
Shares Outstanding23,656,336
10 Day Avg. Volume1,123
30 Day Avg. Volume1,187
Financial Highlights & Ratios
PEG Ratio-0.98
Price to Book (P/B)2.09
Price to Sales (P/S)1.22
P/FCF Ratio-76.05
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Historical Revenue GrowthConsistent multi-year revenue expansion indicates the company has built distribution, product adoption and market traction, creating a larger, more predictable revenue base. That scale supports reinvestment in R&D and capacity and reduces execution risk over the next several months.
Balance Sheet StrengthA stable equity base with moderate leverage provides financial flexibility to fund growth, absorb shocks and pursue necessary capital expenditure. Manageable debt limits refinancing risk and preserves options for tactical investments or working capital needs over a medium-term horizon.
Recovered Operating Cash FlowRecovery in operating cash flow shows the core business has regained cash-generating ability, which supports funding operations and selective investments without persistent external financing. Sustained OCF improvement can stabilize free cash flow and support strategic initiatives.
Bears Say
Volatile Free Cash FlowMaterial volatility and a recent negative free cash flow trend weaken self-funding capacity and raise liquidity risk. This instability can constrain capex, delay strategic projects, and increase reliance on debt or equity financing, affecting resilience over the coming months.
Margin CompressionDeclining gross profit and compressed EBIT/net margins signal margin pressure from costs or pricing erosion. Even with revenue scale, weaker margins reduce operating leverage and cash conversion, undermining durable profitability and the ability to fund growth without margin recovery.
Recent Revenue ContractionA materially negative recent revenue growth metric indicates a significant contraction versus prior periods. That swing undermines the historical growth narrative and raises questions about demand durability, customer retention or one-off disruptions that could persist into the medium term.
Bafna Pharmaceuticals Limited News
BAFNAPH FAQ
What was Bafna Pharmaceuticals Limited’s price range in the past 12 months?
Bafna Pharmaceuticals Limited lowest stock price was ₹71.65 and its highest was ₹204.95 in the past 12 months.
What is Bafna Pharmaceuticals Limited’s market cap?
Bafna Pharmaceuticals Limited’s market cap is ₹2.63B.
When is Bafna Pharmaceuticals Limited’s upcoming earnings report date?
Bafna Pharmaceuticals Limited’s upcoming earnings report date is Jun 03, 2026 which is in 58 days.
How were Bafna Pharmaceuticals Limited’s earnings last quarter?
Bafna Pharmaceuticals Limited released its earnings results on Feb 11, 2026. The company reported ₹0.776 earnings per share for the quarter, beating the consensus estimate of N/A by ₹0.776.
Is Bafna Pharmaceuticals Limited overvalued?
According to Wall Street analysts Bafna Pharmaceuticals Limited’s price is currently Overvalued.
Does Bafna Pharmaceuticals Limited pay dividends?
Bafna Pharmaceuticals Limited pays a Notavailable dividend of ₹0.6 which represents an annual dividend yield of N/A. See more information on Bafna Pharmaceuticals Limited dividends here
What is Bafna Pharmaceuticals Limited’s EPS estimate?
Bafna Pharmaceuticals Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Bafna Pharmaceuticals Limited have?
Bafna Pharmaceuticals Limited has 23,656,336 shares outstanding.
What happened to Bafna Pharmaceuticals Limited’s price movement after its last earnings report?
Bafna Pharmaceuticals Limited reported an EPS of ₹0.776 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 1.563%.
Which hedge fund is a major shareholder of Bafna Pharmaceuticals Limited?
Currently, no hedge funds are holding shares in IN:BAFNAPH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bafna Pharmaceuticals Limited
Bafna Pharmaceuticals Limited manufactures and sells finished pharmaceutical formulations in India. The company provides delayed and sustained release, chewable, and orally disintegrating tablets. It also exports its products. Bafna Pharmaceuticals Limited was founded in 1981 and is based in Chennai, India.
Technical Analysis
Aarey Drugs & Pharmaceuticals Ltd.
―
Alpa Laboratories Limited
―
Bal Pharma Limited
―
Krebs Biochemicals & Industries Ltd.
―
Mangalam Drugs & Organics Ltd.
―